Print Page  Close Window

Investor Overview

Corporate Profile
Eiger is a clinical-stage biopharmaceutical company committed to developing and commercializing novel products for the treatment of rare diseases. Eiger has built a diverse, late-stage portfolio of well-characterized product candidates with the potential to address diseases for which the unmet medical need is high, a novel biology for treatment has been identified, and for which an effective therapy is urgently needed. The Eiger management team has extensive experience in the clinical development a... More >>
Stock Quote
EIGR (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$11.00
Change (%) Stock is Down 0.2 (1.79%)
Volume81,878
Data as of 07/17/18 12:35 p.m. ET
Refresh quote
Recent NewsMore >>
DateTitle
06/04/18Eiger Announces HDV Phase 2 Program Oral Presentation and Investigator / Key Opinion Leader Reception for Planned HDV Phase 3 D-LIVR Study at Global Hepatitis Summit 2018™
05/30/18Eiger BioPharmaceuticals to Present at Jefferies 2018 Global Healthcare Conference
05/24/18Eiger BioPharmaceuticals Prices Previously Announced Public Offering of Common Stock
05/23/18Eiger BioPharmaceuticals Announces Proposed Public Offering of Common Stock
Upcoming EventsMore >>
DateTitle
08/14/18
through
08/15/18
Eiger BioPharmaceuticals at the Wedbush PacGrow Conference
09/04/18
through
09/06/18
Eiger BioPharmaceuticals at the Rodman and Renshaw Conference
10/02/18
Eiger BioPharmaceuticals at the Ladenburg Thalmann 2018 Healthcare Conference
LocationNew York City, NY
What's New
There are currently no items available.
Receive E-mail Alerts
Sign up to receive e-mail alerts whenever Eiger BioPharmaceuticals posts new information to the site. Just enter your e-mail address and click Submit.
 
Data provided by Nasdaq. Minimum 15 minutes delayed.